• Chen Li and JinHua Hu.
• Liver Failure Treatment and Research Center, 302 Military Hospital, Beijing, P.R. China.
• Medicine (Baltimore). 2018 Apr 1; 97 (15): e0416e0416.

RationaleDirect-acting antivirals (DAAs) are the first-line treatment for patients with chronic hepatitis C virus (HCV) infection. However, its effects on patients with acute HCV infection are poorly understood, and the data for treatment of DAAs for genotype 2 acute monoinfection patients with HCV are lacking.Patient ConcernsIn this case report, a 26 year-old Chinese female acquired a tattoo and developed fatigue, nausea, and anorexia. Laboratory tests showed abnormal liver function.DiagnosesFive months after the patient acquired a tattoo, laboratory tests showed anti-HCV antibody titers were 26.0 s/co, HCV RNA was 5.74×10 IU/mL, and HCV genotype was 2a. The patient was diagnosed with acute hepatitis C (AHC).InterventionsHCV RNA did not have spontaneous clearance 12 weeks after the infection of the patient. The patient received sofosbuvir (SOF) and daclatasvir (DCV) combination treatment for 12 weeks.OutcomesLaboratory tests showed HCV RNA was undetectable at weeks 4, and anti-HCV antibody was in seroconversion at weeks 12 during treatment. The patient achieved a sustained virological response 36 weeks after the end of treatment.LessonsPatients with acute HCV genotype 2 monoinfection would benefit from antiviral treatment with SOF and DCV.

29 keywords...

hide…